FDA declines to approve Sarepta's second Duchenne drug
(Reuters) - The U.S. Food and Drug Administration declined to approve Sarepta Therapeutics Inc's newest treatment for Duchenne muscular dystrophy (DMD), a rare muscle-wasting disorder that mainly affects boys, the company said on Monday.
The health agency cited safety concerns, including risk of infection and kidney toxicity. The Cambridge, Massachusetts-based company already has one approved treatment for DMD on the market.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.